NEW YORK (GenomeWeb) – Accelerate Diagnostics said on Thursday that its total revenues shot up to $122,000 in 2014 from $48,000 in 2013. 

In its Form 10-K filed with the US Securities and Exchange Commission, the company said that the increase resulted from deferred royalties recognized last year. In 2014 Accelerate recognized $69,000 in deferred revenues compared to $10,000 in 2013. 

All revenues for both years consisted of licensing and royalty revenues. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.